Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of c-ATT versus CHOP in untreated high-risk T-cell lymphoma
ChiCTR-TRC-08000246Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, doxorubicin, vincristine, prednisone and c-ATT regimen in T-cell lymphoma (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: 5-year overall survival. Started Jan 2008; status: recruiting.
02
Drugs
cyclophosphamidedoxorubicinvincristineprednisonec-ATT regimen
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on ChiCTR-TRC-08000246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-08000246.